iOS
Android
Facebook
WhatsApp
Twitter
GRELOR co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with • acute coronary syndromes (ACS) or • a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event
Ticagrelor 60mg
Patients taking GRELOR should also take a daily low maintenance dose of ASA 75-150 mg, unless specifically contraindicated.
Bleeding risk The use of ticagrelor in patients at known increased risk for bleeding should be balanced against the benefit in terms of prevention of atherothrombotic events. If clinically indicated, ticagrelor should be used with caution in the following patient groups: • Patients with a propensity to bleed (e.g. due to recent trauma, recent surgery, coagulation disorders, active or recent gastrointestinal bleeding) or who are at increased risk of trauma. The use of ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial haemorrhage, and in patients with severe hepatic impairment. • Patients with concomitant administration of medicinal products that may increase the risk of bleeding (e.g. non-steroidal antiinflammatory drugs (NSAIDs), oral anticoagulants and/or fibrinolytics) within 24 hours of ticagrelor dosing.
KES 2,484.00
Delivery within 4 hours on all orders placed between 8:00 AM & 8:00 PM
